The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (≥80 % full dose) of peginterferon alfa-2a: A prospective randomized multicenter trial

Jung Hyun Kwon; Si Hyun Bae; Youn Jae Lee; Jin Woo Lee; Young Seok Kim; Jae Seok Hwang; Won Young Tak; Jeong Won Jang; Byung Seok Lee; June Sung Lee; Chun Kyon Lee; Soon Koo Baik; Neung Hwa Park; Tae Hee Lee; Dong Joon Kim; Jae Seok Choi; Jae Gook Shin; Hyeon Woo Yim

doi:10.1007/s12072-013-9472-x

The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (≥80 % full dose) of peginterferon alfa-2a: A prospective randomized multicenter trial

Jung Hyun Kwon, Si Hyun Bae, Youn Jae Lee, Jin Woo Lee, Young Seok Kim, Jae Seok Hwang, Won Young Tak, Jeong Won Jang, Byung Seok Lee, June Sung Lee, Chun Kyon Lee, Soon Koo Baik, Neung Hwa Park, Tae Hee Lee, Dong Joon Kim, Jae Seok Choi, Jae Gook Shin, Hyeon Woo Yim

Internal Medicine

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Purpose: A high rate of sustained viral response (SVR) in Koreans with chronic hepatitis C (CHC) is related to a favorable IL28B genotype. We compared two dosing strategies for peginterferon alfa-2a in Koreans with CHC and defined the combined effect of polymorphisms and dosing on the virological response. Methods: A total of 178 treatment-naïve patients with CHC genotype 1 were prospectively enrolled. All patients were randomly assigned to treatment with one of two peginterferon alfa-2a regimens: 180 μg per week for 48 weeks (full-dose group) or 180 μg per week during the first 12 weeks followed by 135 μg per week for the next 36 weeks (dose-reduction group). Polymorphisms related to IL28B, ITPA, C20orf194 and SLC29A1 were studied. Results: SVR rates did not differ between the full-dose and dose-reduction groups (56.5 and 51.2 %, respectively, p = 0.474). The frequency of additional reductions of the peginterferon dose because of adverse events was higher in the full-dose group than in the dose-reduction group. SVR rates in patients homozygous for the IL28B major allele were higher than those in patients for the other IL28B alleles. For patients with unfavorable IL28B genotypes, SVR was less likely to be achieved in the dose-reduction group than in the full-dose group. Conclusions: In Koreans with HCV genotype 1, the virological response to treatment did not differ between a full dose and reduced dose (≥80 % of full dose) of peginterferon alfa-2a. However, in the patients with unfavorable IL28B genotypes, the full-dose treatment of peginterferon alfa-2a may be beneficial.

Original language	English
Pages (from-to)	1000-1009
Number of pages	10
Journal	Hepatology International
Volume	7
Issue number	4
DOIs	https://doi.org/10.1007/s12072-013-9472-x
Publication status	Published - 2013 Oct

Bibliographical note

Funding Information:
Acknowledgements Kwon JH, Bae SH, Lee YJ planned the study design and analyzed and interpreted the data. JH Kwon drafted the manuscript. HY Yim supported the randomization of patients and statistical analysis. YJ Lee, JG Shin and JS Choi performed the SNP study. All the authors prospectively enrolled and treated patients and acquired the data. All authors had access to the study data and reviewed and approved the final manuscript. This study was supported by a grant from the research supporting program of the Korean Association for the Study of the Liver.

All Science Journal Classification (ASJC) codes

Hepatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s12072-013-9472-x

Fingerprint

Dive into the research topics of 'The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (≥80 % full dose) of peginterferon alfa-2a: A prospective randomized multicenter trial'. Together they form a unique fingerprint.

Cite this

Kwon, J. H., Bae, S. H., Lee, Y. J., Lee, J. W., Kim, Y. S., Hwang, J. S., Tak, W. Y., Jang, J. W., Lee, B. S., Lee, J. S., Lee, C. K., Baik, S. K., Park, N. H., Lee, T. H., Kim, D. J., Choi, J. S., Shin, J. G., & Yim, H. W. (2013). The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (≥80 % full dose) of peginterferon alfa-2a: A prospective randomized multicenter trial. Hepatology International, 7(4), 1000-1009. https://doi.org/10.1007/s12072-013-9472-x

@article{5acd87e0380a4402a2ac3f3c545ace98,

title = "The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (≥80 % full dose) of peginterferon alfa-2a: A prospective randomized multicenter trial",

abstract = "Purpose: A high rate of sustained viral response (SVR) in Koreans with chronic hepatitis C (CHC) is related to a favorable IL28B genotype. We compared two dosing strategies for peginterferon alfa-2a in Koreans with CHC and defined the combined effect of polymorphisms and dosing on the virological response. Methods: A total of 178 treatment-na{\"i}ve patients with CHC genotype 1 were prospectively enrolled. All patients were randomly assigned to treatment with one of two peginterferon alfa-2a regimens: 180 μg per week for 48 weeks (full-dose group) or 180 μg per week during the first 12 weeks followed by 135 μg per week for the next 36 weeks (dose-reduction group). Polymorphisms related to IL28B, ITPA, C20orf194 and SLC29A1 were studied. Results: SVR rates did not differ between the full-dose and dose-reduction groups (56.5 and 51.2 %, respectively, p = 0.474). The frequency of additional reductions of the peginterferon dose because of adverse events was higher in the full-dose group than in the dose-reduction group. SVR rates in patients homozygous for the IL28B major allele were higher than those in patients for the other IL28B alleles. For patients with unfavorable IL28B genotypes, SVR was less likely to be achieved in the dose-reduction group than in the full-dose group. Conclusions: In Koreans with HCV genotype 1, the virological response to treatment did not differ between a full dose and reduced dose (≥80 % of full dose) of peginterferon alfa-2a. However, in the patients with unfavorable IL28B genotypes, the full-dose treatment of peginterferon alfa-2a may be beneficial.",

author = "Kwon, {Jung Hyun} and Bae, {Si Hyun} and Lee, {Youn Jae} and Lee, {Jin Woo} and Kim, {Young Seok} and Hwang, {Jae Seok} and Tak, {Won Young} and Jang, {Jeong Won} and Lee, {Byung Seok} and Lee, {June Sung} and Lee, {Chun Kyon} and Baik, {Soon Koo} and Park, {Neung Hwa} and Lee, {Tae Hee} and Kim, {Dong Joon} and Choi, {Jae Seok} and Shin, {Jae Gook} and Yim, {Hyeon Woo}",

note = "Funding Information: Acknowledgements Kwon JH, Bae SH, Lee YJ planned the study design and analyzed and interpreted the data. JH Kwon drafted the manuscript. HY Yim supported the randomization of patients and statistical analysis. YJ Lee, JG Shin and JS Choi performed the SNP study. All the authors prospectively enrolled and treated patients and acquired the data. All authors had access to the study data and reviewed and approved the final manuscript. This study was supported by a grant from the research supporting program of the Korean Association for the Study of the Liver.",

year = "2013",

month = oct,

doi = "10.1007/s12072-013-9472-x",

language = "English",

volume = "7",

pages = "1000--1009",

journal = "Hepatology International",

issn = "1936-0533",

publisher = "Springer New York",

number = "4",

}

Kwon, JH, Bae, SH, Lee, YJ, Lee, JW, Kim, YS, Hwang, JS, Tak, WY, Jang, JW, Lee, BS, Lee, JS, Lee, CK, Baik, SK, Park, NH, Lee, TH, Kim, DJ, Choi, JS, Shin, JG & Yim, HW 2013, 'The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (≥80 % full dose) of peginterferon alfa-2a: A prospective randomized multicenter trial', Hepatology International, vol. 7, no. 4, pp. 1000-1009. https://doi.org/10.1007/s12072-013-9472-x

The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (≥80 % full dose) of peginterferon alfa-2a : A prospective randomized multicenter trial. / Kwon, Jung Hyun; Bae, Si Hyun; Lee, Youn Jae et al.

In: Hepatology International, Vol. 7, No. 4, 10.2013, p. 1000-1009.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (≥80 % full dose) of peginterferon alfa-2a

T2 - A prospective randomized multicenter trial

AU - Kwon, Jung Hyun

AU - Bae, Si Hyun

AU - Lee, Youn Jae

AU - Lee, Jin Woo

AU - Kim, Young Seok

AU - Hwang, Jae Seok

AU - Tak, Won Young

AU - Jang, Jeong Won

AU - Lee, Byung Seok

AU - Lee, June Sung

AU - Lee, Chun Kyon

AU - Baik, Soon Koo

AU - Park, Neung Hwa

AU - Lee, Tae Hee

AU - Kim, Dong Joon

AU - Choi, Jae Seok

AU - Shin, Jae Gook

AU - Yim, Hyeon Woo

N1 - Funding Information: Acknowledgements Kwon JH, Bae SH, Lee YJ planned the study design and analyzed and interpreted the data. JH Kwon drafted the manuscript. HY Yim supported the randomization of patients and statistical analysis. YJ Lee, JG Shin and JS Choi performed the SNP study. All the authors prospectively enrolled and treated patients and acquired the data. All authors had access to the study data and reviewed and approved the final manuscript. This study was supported by a grant from the research supporting program of the Korean Association for the Study of the Liver.

PY - 2013/10

Y1 - 2013/10

N2 - Purpose: A high rate of sustained viral response (SVR) in Koreans with chronic hepatitis C (CHC) is related to a favorable IL28B genotype. We compared two dosing strategies for peginterferon alfa-2a in Koreans with CHC and defined the combined effect of polymorphisms and dosing on the virological response. Methods: A total of 178 treatment-naïve patients with CHC genotype 1 were prospectively enrolled. All patients were randomly assigned to treatment with one of two peginterferon alfa-2a regimens: 180 μg per week for 48 weeks (full-dose group) or 180 μg per week during the first 12 weeks followed by 135 μg per week for the next 36 weeks (dose-reduction group). Polymorphisms related to IL28B, ITPA, C20orf194 and SLC29A1 were studied. Results: SVR rates did not differ between the full-dose and dose-reduction groups (56.5 and 51.2 %, respectively, p = 0.474). The frequency of additional reductions of the peginterferon dose because of adverse events was higher in the full-dose group than in the dose-reduction group. SVR rates in patients homozygous for the IL28B major allele were higher than those in patients for the other IL28B alleles. For patients with unfavorable IL28B genotypes, SVR was less likely to be achieved in the dose-reduction group than in the full-dose group. Conclusions: In Koreans with HCV genotype 1, the virological response to treatment did not differ between a full dose and reduced dose (≥80 % of full dose) of peginterferon alfa-2a. However, in the patients with unfavorable IL28B genotypes, the full-dose treatment of peginterferon alfa-2a may be beneficial.

AB - Purpose: A high rate of sustained viral response (SVR) in Koreans with chronic hepatitis C (CHC) is related to a favorable IL28B genotype. We compared two dosing strategies for peginterferon alfa-2a in Koreans with CHC and defined the combined effect of polymorphisms and dosing on the virological response. Methods: A total of 178 treatment-naïve patients with CHC genotype 1 were prospectively enrolled. All patients were randomly assigned to treatment with one of two peginterferon alfa-2a regimens: 180 μg per week for 48 weeks (full-dose group) or 180 μg per week during the first 12 weeks followed by 135 μg per week for the next 36 weeks (dose-reduction group). Polymorphisms related to IL28B, ITPA, C20orf194 and SLC29A1 were studied. Results: SVR rates did not differ between the full-dose and dose-reduction groups (56.5 and 51.2 %, respectively, p = 0.474). The frequency of additional reductions of the peginterferon dose because of adverse events was higher in the full-dose group than in the dose-reduction group. SVR rates in patients homozygous for the IL28B major allele were higher than those in patients for the other IL28B alleles. For patients with unfavorable IL28B genotypes, SVR was less likely to be achieved in the dose-reduction group than in the full-dose group. Conclusions: In Koreans with HCV genotype 1, the virological response to treatment did not differ between a full dose and reduced dose (≥80 % of full dose) of peginterferon alfa-2a. However, in the patients with unfavorable IL28B genotypes, the full-dose treatment of peginterferon alfa-2a may be beneficial.

UR - http://www.scopus.com/inward/record.url?scp=84890566283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890566283&partnerID=8YFLogxK

U2 - 10.1007/s12072-013-9472-x

DO - 10.1007/s12072-013-9472-x

M3 - Article

AN - SCOPUS:84890566283

SN - 1936-0533

VL - 7

SP - 1000

EP - 1009

JO - Hepatology International

JF - Hepatology International

IS - 4

ER -

The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (≥80 % full dose) of peginterferon alfa-2a: A prospective randomized multicenter trial

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this